shutterstock_1960556293_molly_woodward
Molly Woodward / Shutterstock.com
15 February 2024Big PharmaLiz Hockley

Pfizer to pay out $93m to end antitrust suit

US pharma firm has not admitted liability as part of agreement with Lipitor buyers following a long-running dispute over a cholesterol drug | Litigation against Sun Pharma’s Ranbaxy will continue.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
1 February 2024   Pharma giants raise concerns about Moderna’s COVID-19 vaccine patents | Company's statements to the FDA and PTAB contain "inconsistencies" | Appeals Board urged to scrutinise assertions.
Big Pharma
30 May 2023   A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.

More on this story

Big Pharma
30 May 2023   A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.
Americas
1 February 2024   Pharma giants raise concerns about Moderna’s COVID-19 vaccine patents | Company's statements to the FDA and PTAB contain "inconsistencies" | Appeals Board urged to scrutinise assertions.

More on this story

Big Pharma
30 May 2023   A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.
Americas
1 February 2024   Pharma giants raise concerns about Moderna’s COVID-19 vaccine patents | Company's statements to the FDA and PTAB contain "inconsistencies" | Appeals Board urged to scrutinise assertions.